Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -95.61% | -53.52% | -43.55% | -33.23% | -62.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.61% | -53.52% | -43.55% | -33.23% | -62.47% |
| Cost of Revenue | -22.63% | -13.97% | 26.22% | 37.17% | 124.94% |
| Gross Profit | 16.56% | 10.55% | -38.53% | -53.55% | -284.69% |
| SG&A Expenses | -21.70% | -15.50% | -8.78% | -3.47% | 4.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.44% | -14.29% | -9.70% | -3.40% | 3.64% |
| Operating Income | 17.69% | 11.66% | 6.56% | -0.11% | -17.02% |
| Income Before Tax | 6.81% | -38.38% | -54.87% | -73.87% | 7.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.81% | -38.38% | -54.87% | -73.87% | 7.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.81% | -38.38% | -54.87% | -73.87% | 7.68% |
| EBIT | 17.69% | 11.66% | 6.56% | -0.11% | -17.02% |
| EBITDA | 17.09% | 11.20% | 6.14% | -0.48% | -17.58% |
| EPS Basic | 19.35% | 22.29% | 48.06% | 54.85% | 77.06% |
| Normalized Basic EPS | 17.63% | 23.89% | 48.98% | 55.55% | 77.58% |
| EPS Diluted | 19.35% | 22.29% | 48.06% | 54.85% | 77.06% |
| Normalized Diluted EPS | 17.63% | 23.89% | 48.98% | 55.55% | 77.58% |
| Average Basic Shares Outstanding | 31.76% | 45.86% | 73.87% | 126.46% | 293.18% |
| Average Diluted Shares Outstanding | 31.76% | 45.86% | 73.87% | 126.46% | 293.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |